Allergy adcom gives unanimous thumbs up to Grastek tablet
By Catherine Shaffer
Thursday, December 12, 2013
In day two of the FDA’s Allergenic Products Advisory Committee meeting, it reviewed Alk-Abello A/S and Merck and Co. Inc.’s Grastek sublingual tablet. Members agreed unanimously that available data support efficacy of Grastek for treatment of Timothy grass pollen-induced allergic rhinitis in patients 5 to 65 years and that adrenaline auto-injectors must be made available for patients at home.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.